Cargando…
Desperately looking for the right target in osteoarthritis: the anti-IL-1 strategy
Blocking IL-1 in patients with knee osteoarthritis is an attractive strategy. Cohen and colleagues report a randomised, placebo-controlled, multiple-dose trial using a monoclonal antibody blocking IL-1 type 1 receptor. They failed to show any positive results in terms of evolution of pain for up to...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3239369/ https://www.ncbi.nlm.nih.gov/pubmed/21888686 http://dx.doi.org/10.1186/ar3436 |
_version_ | 1782219177619095552 |
---|---|
author | Chevalier, Xavier Conrozier, Thierry Richette, Pascal |
author_facet | Chevalier, Xavier Conrozier, Thierry Richette, Pascal |
author_sort | Chevalier, Xavier |
collection | PubMed |
description | Blocking IL-1 in patients with knee osteoarthritis is an attractive strategy. Cohen and colleagues report a randomised, placebo-controlled, multiple-dose trial using a monoclonal antibody blocking IL-1 type 1 receptor. They failed to show any positive results in terms of evolution of pain for up to 12 weeks, in line with the former trials using intraarticular injections of IL-1 receptor antagonist. A trend was observed, however, in a subgroup of patients with high level of pain at baseline. Although these data may suggest cessation of IL-1 therapy in osteoarthritis, other methods such as limited intraarticular anti-IL-1 delivery should still be considered. |
format | Online Article Text |
id | pubmed-3239369 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-32393692012-02-26 Desperately looking for the right target in osteoarthritis: the anti-IL-1 strategy Chevalier, Xavier Conrozier, Thierry Richette, Pascal Arthritis Res Ther Editorial Blocking IL-1 in patients with knee osteoarthritis is an attractive strategy. Cohen and colleagues report a randomised, placebo-controlled, multiple-dose trial using a monoclonal antibody blocking IL-1 type 1 receptor. They failed to show any positive results in terms of evolution of pain for up to 12 weeks, in line with the former trials using intraarticular injections of IL-1 receptor antagonist. A trend was observed, however, in a subgroup of patients with high level of pain at baseline. Although these data may suggest cessation of IL-1 therapy in osteoarthritis, other methods such as limited intraarticular anti-IL-1 delivery should still be considered. BioMed Central 2011 2011-08-26 /pmc/articles/PMC3239369/ /pubmed/21888686 http://dx.doi.org/10.1186/ar3436 Text en Copyright ©2011 BioMed Central Ltd |
spellingShingle | Editorial Chevalier, Xavier Conrozier, Thierry Richette, Pascal Desperately looking for the right target in osteoarthritis: the anti-IL-1 strategy |
title | Desperately looking for the right target in osteoarthritis: the anti-IL-1 strategy |
title_full | Desperately looking for the right target in osteoarthritis: the anti-IL-1 strategy |
title_fullStr | Desperately looking for the right target in osteoarthritis: the anti-IL-1 strategy |
title_full_unstemmed | Desperately looking for the right target in osteoarthritis: the anti-IL-1 strategy |
title_short | Desperately looking for the right target in osteoarthritis: the anti-IL-1 strategy |
title_sort | desperately looking for the right target in osteoarthritis: the anti-il-1 strategy |
topic | Editorial |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3239369/ https://www.ncbi.nlm.nih.gov/pubmed/21888686 http://dx.doi.org/10.1186/ar3436 |
work_keys_str_mv | AT chevalierxavier desperatelylookingfortherighttargetinosteoarthritistheantiil1strategy AT conrozierthierry desperatelylookingfortherighttargetinosteoarthritistheantiil1strategy AT richettepascal desperatelylookingfortherighttargetinosteoarthritistheantiil1strategy |